Sanofi (NASDAQ:SNY) Cut to Buy at StockNews.com

StockNews.com cut shares of Sanofi (NASDAQ:SNY) from a strong-buy rating to a buy rating in a report released on Wednesday morning.

Separately, Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a buy rating in a research note on Friday, July 26th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $57.46 on Wednesday. The stock has a market cap of $145.53 billion, a PE ratio of 28.87, a P/E/G ratio of 1.64 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a 50-day moving average of $53.36 and a 200-day moving average of $50.03. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the prior year, the firm earned $0.95 EPS. The business’s revenue was up 7.8% on a year-over-year basis. On average, sell-side analysts anticipate that Sanofi will post 4.23 EPS for the current year.

Institutional Trading of Sanofi

Institutional investors have recently bought and sold shares of the business. Cascade Investment Advisors Inc. grew its holdings in shares of Sanofi by 4.7% during the 1st quarter. Cascade Investment Advisors Inc. now owns 34,359 shares of the company’s stock worth $1,670,000 after purchasing an additional 1,535 shares in the last quarter. Vestal Point Capital LP bought a new position in Sanofi in the 4th quarter valued at about $14,919,000. Dynamic Advisor Solutions LLC raised its position in shares of Sanofi by 39.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after buying an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC acquired a new position in shares of Sanofi in the 2nd quarter valued at approximately $13,725,000. Finally, Oxbow Advisors LLC bought a new stake in shares of Sanofi during the 4th quarter worth approximately $4,689,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.